XXXII\textsuperscript{nd} International Workshop
on Helicobacter & Microbiota in Inflammation and Cancer

EHMSG Postgraduate Course
“Microbiota: from metabolism to immunity and fecal microbial transplantation - pearls for the clinician”

September 5 – 7, 2019 | Innsbruck | Austria
XXXII\textsuperscript{nd} International Workshop  
on Helicobacter & Microbiota in Inflammation and Cancer  
EHMSG Postgraduate Course  
“Microbiota: from metabolism to immunity and fecal microbial transplantation - pearls for the clinician”  
September 5 – 7, 2019 | Innsbruck | Austria
AWARDEES OF THE MARSHALL AND WARREN MEDAL

2019  Guillermo Perez-Perez, New York, NY, United States
2018  Kenneth McColl, Glasgow, United Kingdom
2017  Jean-Charles Delchier, France
2016  Ken Sugano, Shimotsuke, Japan
2015  Heidi-Ingrid Maaroos, Tartu, Estonia
2014  Manfred Kist, Freiburg, Germany
2013  Masahiro Asaka, Sapporo, Japan
2012  Richard Hunt, Hamilton, ON, Canada
2011  Samy Cadranel, Brussels, Belgium
2010  Reinhold W. Stockbrügger, Maastricht, The Netherlands
2009  Pelayo Correa, Nashville, TN, United States
2008  Timo Kosunen, Helsinki, Finland
2007  Mike Dixon, Leeds, United Kingdom
2006  Barry Marshall, Perth, Australia & Stanislaw Konturek, Cracow, Poland

NEXT EHMSG WORKSHOP

Glasgow, United Kingdom | September 10 - 12, 2020
Dear Colleagues, dear friends,

A warm welcome from my side to the annual meeting of EHMSG in Innsbruck, Austria. EHMSG has evolved over the last years as a very dynamic and innovative international society and now tries to cover in its annual meeting both highlights and recent developments from the „Helicobacter“ and „microbiota“ field.

It is my pleasure to announce that we were able to organize a world-class postgraduate course on gut microbiota on September 5th covering very diverse aspects of microbiota research. Top international and highly respected colleagues will present their state-of-the-art research. In the original programme of this meeting excellent original research from both the Helicobacter and microbiota field will be presented.

Innsbruck, a small but wonderful city in the heart of the Alps is a perfect host for such an international meeting. Our congress venue is located in the middle of the city and constitutes a perfect location for this type of meeting. We are proud to welcome colleagues from all over the world to attend this year’s EHMSG meeting. The special and almost familiar atmosphere of this meeting will allow to enjoy not only top science but also friendship and loveliness of our city and country.

With my best wishes

Herbert Tilg
President of EHMSG
European Helicobacter & Microbiota Study Group EHMSG

President of the EHMSG
Herbert Tilg, Austria

Members and International Scientific Committee
Leif P. Andersen, Denmark
Lars Engstrang, Sweden
Antonio Gasbarrini, Italy
Javier P. Gisbert, Spain
Georgina Hold, United Kingdom
Ernst Kuipers, The Netherlands
Marcis Leja, Latvia
José C. Machado, Portugal
Peter Malfertheiner, Germany
Francis Mégraud, France
Colm A. O’Morain, Ireland
Mirjana Rajilic-Stovanovic, Serbia
Ari P. Ristimäki, Finland
Theodore Rokkas, Greece
Annemieke Smet, Belgium

Local Committee

President
Herbert Tilg, Austria

Members
Timon Adolph, Innsbruck
Werner Dolak, Vienna
Maria Effenberger, Innsbruck
Christoph Högenauer, Graz
Günter Krejs, Graz
Patrizia Kump, Graz
Athanasios Makristathis, Vienna
Alexander Moschen, Innsbruck
Christoph Steininger, Vienna

Emeritus Members
Anthony Axon, United Kingdom
Michel A.L. Deltenre, Belgium
Bram Flahou, Belgium
Giovanni Gasbarrini, Italy
Alexander M. Hirschl, Austria
Pierre Michetti, Switzerland
José M. Pajares Garcia, Spain
Ashley B. Price, United Kingdom
Mario G. Quina, Portugal (†)
Erik A.J. Rauws, The Netherlands
Pentti I. Sipponen, Finland
Torkel M. Wadström, Sweden

Corresponding Fellows
Niyaz Ahmed, India
Dmitry Bordin, Russia
Luis G. Vaz Coelho, Brazil
Jae Gyu Kim, Korea
Varocha Mahachai, Thailand
Yaron Niv, Israel
Chun-Ying Wu, Taiwan
Yoshio Yamaoka, Japan
Weicheng You, China

Honorary Members
Franco Bazzoli, Italy
James G. Fox, United States
David Y. Graham, United States
Adrian Lee, Australia
Barry Marshall , Australia
Guido N.J. Tytgat, The Netherlands

Organizing Office

Core Agency
Scientific and Administrative Secretariat
Vienna Medical Academy
Catherine Tomek
Alser Strasse 4
A-1090 Vienna, Austria
Phone: +43 1 405 13 83 18
Fax: +43 1 407 82 74
Email: workshop@ehmsg.org

Workshops of the EHMSG

- Bordeaux (1988)
- Ulm (1989)
- Toledo (1990)
- Bologna (1991)
- Dublin (1992)
- Brussels (1993)
- Houston (1994)
- Copenhagen (1996)
- Lisbon (1997)
- Budapest (1998)
- Helsinki (1999)
- Rome (2000)
- Strasbourg (2001)
- Athens (2002)
- Vienna (2004)
- Copenhagen (2005)
- Wroclaw (2006)
- Istanbul (2007)
- Riga (2008)
- Porto (2009)
- Rotterdam (2010)
- Dublin (2011)
- Ljubljana (2012)
- Madrid (2013)
- Rome (2014)
- Nicosia (2015)
- Magdeburg (2016)
- Bordeaux (2017)
- Kaunas (2018)
- Innsbruck (2019)
Invitation

www.ehmsg.org

XXXIIIrd International Workshop on Helicobacter & Microbiota in Inflammation and Cancer

September 10 – 12, 2020 | Glasgow | United Kingdom
# Programme at a Glance

## Thursday, September 5, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Venue</th>
</tr>
</thead>
</table>
| 08.00 - 17.00 hrs | EHMSG Postgraduate Course  
"Microbiota: from metabolism to immunity and fecal microbial transplantation-pearls for the clinician" | Room Brussels          |
| 17.00 - 18.30 hrs | EHMSG Far East Symposium  
Omics for Helicobacter | Room Brussels          |
| 18.30 - 19.30 hrs | Networking Event                                                     | Exhibition Area of the Conference Venue |

## Friday, September 6, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 19.15 hrs</td>
<td>EHMSG 2019 Conference</td>
<td>Room Innsbruck</td>
</tr>
<tr>
<td>08.30 – 09.30 hrs</td>
<td>Introductory Lectures</td>
<td>Room Innsbruck</td>
</tr>
<tr>
<td>09.30 – 11.10 hrs</td>
<td>Symposium: Microbiota and GI/liver cancer</td>
<td>Room Innsbruck</td>
</tr>
<tr>
<td>11.10 – 11.30 hrs</td>
<td>Coffee Break</td>
<td>Exhibition Area</td>
</tr>
<tr>
<td>11.30 – 13.10 hrs</td>
<td>Symposium: Gastric Carcinogenesis</td>
<td>Room Innsbruck</td>
</tr>
<tr>
<td>13.10 – 14.00 hrs</td>
<td>Lunch Break &amp; Poster Viewing</td>
<td>Exhibition Area</td>
</tr>
<tr>
<td>14.00 – 14.30 hrs</td>
<td>Impact of H. pylori eradication on gastric cancer risk</td>
<td>Room Innsbruck</td>
</tr>
</tbody>
</table>
| 14.30 – 16.00 hrs | Parallel Workshops from Submitted Abstracts  
Workshop W1. | Diagnosis & Epidemiology                                              | Room Innsbruck         |
| 14.30 – 16.00 hrs | Parallel Workshops from Submitted Abstracts  
Workshop W2. | H. pylori pathogenesis                                                 | Room Brussels          |
| 16.00 – 16.30 hrs | Coffee Break                                                         | Exhibition Area         |
| 16.30 – 17.30 hrs | State of the Art Lectures                                             | Room Innsbruck         |
| 17.30 – 19.15 hrs | Parallel Workshops from Submitted Abstracts  
Workshop W3. | Treatment of Helicobacter Infection I                                | Room Innsbruck         |
| 17.30 – 19.15 hrs | Parallel Workshops from Submitted Abstracts  
Workshop W4. | Gastric Carcinogenesis                                                | Room Brussels          |
| 20.00 hrs | Networking Dinner                                                   | Restaurant Stiftskeller |
### PROGRAMME AT A GLANCE

**Saturday, September 7, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 – 18.30 hrs</td>
<td>EHMSG 2019 Conference</td>
<td>Room Innsbruck</td>
</tr>
<tr>
<td>08.00 – 09.40 hrs</td>
<td>Symposium: Modulation of microbiota</td>
<td>Room Innsbruck</td>
</tr>
<tr>
<td>09.40 – 10.30 hrs</td>
<td>Coffee Break</td>
<td>Exhibition Area</td>
</tr>
<tr>
<td>10.30 – 12.00 hrs</td>
<td>Symposium: Helicobacter and other Microbiota in Extragastric Diseases</td>
<td>Room Innsbruck</td>
</tr>
<tr>
<td>12.00 - 13.00 hrs</td>
<td>Industry-Sponsored Satellite Symposium</td>
<td>Room Innsbruck</td>
</tr>
<tr>
<td>13.00 – 14.00 hrs</td>
<td>Lunch Break &amp; Poster Viewing</td>
<td>Exhibition Area</td>
</tr>
<tr>
<td>14.00 – 15.30 hrs</td>
<td>Parallel Workshops from Submitted Abstracts, Workshop W5.</td>
<td>Treatment of Helicobacter Infection II</td>
</tr>
<tr>
<td>14.00 – 15.30 hrs</td>
<td>Parallel Workshops from Submitted Abstracts, Workshop W6.</td>
<td>Microbiota in Health and Disease</td>
</tr>
<tr>
<td>15.30 – 16.00 hrs</td>
<td>Coffee Break</td>
<td>Exhibition Area</td>
</tr>
<tr>
<td>16.00 – 17.30 hrs</td>
<td>Symposium: Treatment of H. pylori infection</td>
<td>Room Innsbruck</td>
</tr>
<tr>
<td>17.30 – 18.00 hrs</td>
<td>Debate: Is <em>Helicobacter pylori</em> relevant in oesophageal diseases?</td>
<td>Room Innsbruck</td>
</tr>
<tr>
<td>18.00 – 18.30 hrs</td>
<td>Closing Session, Awarding of the Marshall and Warren Medal to Guillermo Perez-Perez (New York, NY, USA) EHMSG Presentation and Poster Awards, Presentation of the next meeting EHMSG 2020 in Glasgow, United Kingdom Closing remarks</td>
<td>Room Innsbruck</td>
</tr>
</tbody>
</table>
EHMSG Postgraduate Course

“Microbiota: from metabolism to immunity and fecal microbial transplantation—pearls for the clinician”

Course directors: Antonio Gasbarrini, Herbert Tilg

Room Brussels

**08.00 – 09.35 hrs** Opening session: State-of-the art lectures

*Chair: Antonio Gasbarrini, Herbert Tilg*

- **08.00 - 08.05** Welcome
  
  Herbert Tilg, Innsbruck, Austria | Antonio Gasbarrini, Rome, Italy

- **08.05 - 08.35** What is a healthy microbiome?
  
  Julian Marchesi, London, United Kingdom

- **08.35 - 09.05** The gut microbiota as major player in metabolic disorders
  
  Fredrik Bäckhed, Gothenburg, Sweden

- **09.05 - 09.35** Microbiota-driven personalized medicine: close to reality?
  
  Eran Elinav, Rehovot, Israel

**09.35 - 10.05 hrs** Coffee Break

**10.05 - 11.45 hrs** The gut microbiota as complex ecosystem: from “big data” to clinical reality

*Chair: Georgina Hold, Marcis Leja*

- **10.05 - 10.30** Microbiota signatures for various diseases: are we there yet?
  
  Lars Engstrand, Stockholm, Sweden

- **10.30 - 10.55** What can be learn from population-based microbiota studies?
  
  Marie Joossens, Leuven, Belgium

- **10.55 - 11.20** Gut epithelial barrier dysfunction and evidence for a circulating microbiome
  
  Remy Burcelin, Toulouse, France

- **11.20 - 11.45** Antibiotics: not only detrimental for the microbiota
  
  Gianluca Ianiro, Rome, Italy

**11.45 – 13.00 hrs** Lunch Break

**13.00 – 14.40 hrs** Inflammatory bowel disorders (IBD) and intestinal microbiota

*Chair: Patrizia Kump, Lars Engstrand*

- **13.00 - 13.25** Gut microbiota composition and IBD: what have we learned?
  
  Harry Sokol, Paris, France

- **13.25 - 13.50** Pro- and prebiotics in IBD
  
  Alessandro Armuzzi, Rome, Italy

- **13.50 - 14.15** Biomarkers associated with FMT outcomes
  
  Nadeem Kaakoush, Sydney, Australia

- **14.15 - 14.40** Faecal microbial transplantation (FMT) and IBD
  
  Patrizia Kump, Graz, Austria
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.40 - 15.15 hrs</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>
| 15.15 – 16.55 hrs | **FMT: solution for many disorders?**  
*Chair: Juozas Kupcinskas, Colm O’Morain* |
| 15.15 - 15.40    | **FMT for Clostridium difficile** and other antibiotics-resistant bacteria  
Giovanni Cammarota, Rome, Italy |
| 15.40 - 16.05    | **FMT for metabolic syndrome, obesity and diabetes**  
Max Nieuwdorp, Amsterdam, The Netherlands |
| 16.05 - 16.30    | **FMT: a role in cancer immunotherapy?**  
Patricia Lepage, Jouy-en-Josas, France |
| 16.30 - 16.55    | **FMT in chronic liver diseases and complications**  
Jasmohan S. Bajaj, Richmond, VA, USA |
| 16.55 - 17.00 hrs | Closing                                                              |

**EHMSG Far East Symposium**

"Omics for Helicobacter"

**Chairs:** Sang Woo Lee, Francis Mégraud, Kentaro Sugano  
*Room Brussels*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 17.00 - 18.30 hrs | **Dynamics of H. pylori genome and methylome variation during early and chronic infection**  
Sebastian Suerbaum, Munich, Germany |
|                 | **Current knowledge of genomics for H. pylori from Far East**  
Yoshio Yamaoka, Oita, Japan |
|                 | **Dynamics of microbial communities in the human stomach and a humanized gastric microbiota mouse model**  
Soon-Kyeong Kwon, Gyeongsang, South Korea |
| 18.30 - 19.30 hrs | **EHMSG 2019 Welcome Reception**                                       |
08.30 - 09.30 hrs  **Introductory Lectures**  
*Room Innsbruck*

Chair: Franco Bazzoli, Herbert Tilg

08.30 - 09.00

**What's hot in Helicobacter pylori?**  
Kentaro Sugano, Japan

09.00 - 09.30

**What's hot in Microbiota?**  
Eran Elinav, Rehovot, Israel

09.30 - 11.00 hrs  **Symposium: Microbiota and GI/liver cancer**  
*Room Innsbruck*

Chair: Lars Engstrand, Herbert Tilg

09.30 - 09.50

**Gastro-duodenal dysbiosis in functional dyspepsia: the missing link?**  
Carmelo Scarpignato, Parma, Italy

09.50 - 10.10

**Microbiota and its role in oesophageal and gastric cancer**  
Ceu Figueiredo, Porto, Portugal

10.10 - 10.30

**H. pylori infections and associated (pre)malignant lesions of the stomach**  
Michiel Mommersteeg, Amsterdam, The Netherlands

10.30 - 10.50

**Microbiota & Liver cancer**  
Francesca Romana Ponziani, Rome, Italy

10.50 - 11.10

**Cancer therapies and microbiota**  
Georgina Hold, Sydney, Australia

11.10 – 11.30 hrs  **Coffee Break**

11.30 - 13.10 hrs  **Symposium: Gastric Carcinogenesis**  
*Room Innsbruck*

Chair: Yong Chan Lee, Ari Ristimäki

11.30 - 11.50

**Do animal models provide answers in gastric carcinogenesis?**  
James Fox, Boston, MA, US

11.50 - 12.10

**Immunopathogenesis in gastric cancer**  
Mario Milco D’Elios, Florence, Italy

12.10 - 12.30

**The role of intestinal metaplasia in gastric carcinogenesis:**

12.30 - 12.50

**The endoscopic & clinical approach**  
Mario Dinis-Ribeiro, Porto, Portugal

12.50 – 13.10

**The histopathological approach**  
Massimo Rugge, Padova, Italy

13.10 – 14.00 hrs  **Lunch Break  Poster Viewing**
### 14.00 - 14.30 hrs
**Impact of H. pylori eradication on gastric cancer risk**
*Room Innsbruck*

**Chair:** Jae Gyu Kim, Marcis Leja

- **In the East**
  - Il Ju Choi, Seoul, Korea

- **In the West**
  - Theodore Rokkas, Athens, Greece

### 14.30 - 16.00 hrs
**Parallel Workshops from Submitted Abstracts 1**

#### Workshop W1. | Diagnosis and Epidemiology
*Room Innsbruck*

**Chair:** Theodore Rokkas, Christoph Steininger

*Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)*

**W1.1**
**Apparent intracellular Helicobacter pylori detected by immunohistochemistry - the missing link in eradication failure**
A. Beer1, H. Hudler2, M. Kundi1, S. Hudler2, M. Hader3, V. Taeuber1, H. Schachner1, S. Gruber2, A. M. Hirsch1, R. Kain1, A. Makristathi1, 1Medical University Vienna, Vienna, Austria, 2Histopathologic practice Winzendorf, Winzendorf, Austria, 3Wilhelminenspital, Vienna, Austria.

**W1.2**
**Impact of implementing a real-time PCR assay on the workflow and laboratory diagnosis of Helicobacter pylori infection from gastric biopsies**
T. Huang, P. Bogaerts, M. Hoebek, W. Bouchahrouf, C. Berhin, Y. Glucpynski, National Reference Center for Helicobacter pylori, Yvoir, Belgium.

**W1.3**
**Impaired sensitivity of invasive tests for Helicobacter pylori infection in patients with severe chronic atrophic gastritis**
L. Koletzko1, K. Schütte2, L. Macke1, R. Vasapoli1, A. Link3, P. Malferttheiner1, C. Schulz1, 1Department of Medicine II, University Hospital, LMU Munich, München, Germany, 2Department of Internal Medicine and Gastroenterology, Niels-Stensen-Kliniken, Osnabrück, Germany, 3Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany.

**W1.4**
**Risk of gastrointestinal bleeding in new or chronic aspirin users after treatment for Helicobacter pylori: A territory-wide cohort study**
C. Guo, K. S. Cheung, E. W. Chan, I. C. Wong, W. K. Leung, University of Hong Kong, Hong Kong, Hong Kong.

**W1.5**
**Racial differences in Helicobacter pylori antibody prevalence by year of birth and demographic factors in a consortium of US adults**
M. G. Varga1, J. Butt2, W. J. Blot3, L. Le Marchand4, C. Haiman5, Y. Chen6, S. Wassertheil-Smoller7, G. Y. F. Ho8, L. E. Tinker9, R. M. Peek3, J. D. Potter9, T. L. Cover3, L. Hendrix2, T. Hyslop2, A. Zeleniuch-Jacquotte6, S. Berndt10, A. Hildesheim10, T. Waterboer11, M. Pawlita11, M. Eppllein2, 1University of North Carolina, Chapel Hill, NC, United States, 2Duke Cancer Institute, Durham, NC, United States, 3Vanderbilt University Medical Center, Nashville, TN, United States, 4University of Hawaii Cancer Center, Honolulu, HI, United States, 5University of Southern California, Los Angeles, CA, United States, 6New York University, New York, NY, United States, 7Albert Einstein College of Medicine, Bronx, NY, United States, 8Northwell Health, Great Neck, NY, United States, 9Fred Hutchinson Cancer Research Center, Seattle, WA, United States, 10National Cancer Institute, Rockville, MD, United States, 11German Cancer Research Center, Heidelberg, Germany.

**W1.6**
**Seroprevalence and determinants of Helicobacter pylori infection in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)**
S. H. Tsang1, M. Avilés-Santa2, C. C. Abnet3, M. O. Brito3, R. D. Burk4, M. L. Davilus3, S. Wassertheil-Smoller4, S. Castaneda5, B. I. Graubard1, B. Thyagarajan6, M. Camargo1, 1National Cancer Institute, Rockville, MD, United States, 2National Institute on Minority Health and Health Disparities, Rockville, MD, United States, 3University of Illinois, Chicago, IL, United States, 4Albert Einstein College of Medicine, Bronx, NY, United States, 5San Diego State University, Calexico, CA, United States, 6University of Minnesota, Minneapolis, MN, United States.
**PROGRAMME FRIDAY, SEPTEMBER 6**

**W1.7**  
**Decreased pepsinogen level in relation to presence of menopause in the GISTAR study population in Latvia**  
J. Aleksejeva1, D. Razuka-Ebela1,2, I. Daugule1,2, I. Polaka2, S. Parshutin2, D. Santare1,2, I. Ebela1, R. Murillo3, R. Herrero3, J. Park3, M. Leja1,2, 1Faculty of Medicine, University of Latvia, Riga, Latvia, 2Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia, 3International Agency for Research on Cancer, Lyon, France.

**14.30 - 16.00 hrs**  
**Parallel Workshops from Submitted Abstracts 2**  
**Workshop W2. | H. pylori and pathogenesis**  
Chair: Annemieke Smet, Christine Josenhans

*Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)*

**W2.1**  
**R-Spondin 3 links gastric epithelial stem cell regeneration to antimicrobial defense against Helicobacter pylori**  
M. Sigal1,2, T. Meyer1, 1Max-Planck-Institute for Infection Biology, Berlin, Germany, 2Charité University Medicine Berlin, Department of Gastroenterology, Berlin, Germany.

**W2.2**  
*Helicobacter pylori CagA induces intestinal metaplasia in normal human gastric epithelial cells*  
T. Meyer, M. Reines, Department of Molecular Biology; Max Planck Institute for Infection Biology, Berlin, Germany.

**W2.3**  
**Inhibition of Autophagy aggravates DNA damage response via Rad51 ubiquitination in response to H. pylori infection.**  

**W2.4**  
**The innate immune molecule NLRC5 protects against Helicobacter-induced gastric B cell lymphomagenesis**  
M. Chonwerawong1, J. Ferrand1, H. Chaudhry1, C. Higgins1, L. Tran1, M. Walker2, P. S. Bathal3, A. Dev4, G. Moore4, W. Sievert4, B. J. Jenkins1, M. D’Elios5, D. J. Philpott6, T. A. Kufer7, R. L. Ferrero1, 1Hudson Institute of Medical Research, Monash University, Melbourne, Australia, 2The University of Newcastle, Newcastle, Australia, 3University of Melbourne, Melbourne, Australia, 4Monash Health, Monash University, Melbourne, Australia, 5University of Florence, Florence, Italy, 6University of Toronto, Toronto, ON, Canada, 7University of Hohenheim, Stuttgart, Germany.

**W2.5**  
**DNA hypermethylation downregulates Telomerase Reverse Transcriptase (TERT) during H. pylori-induced chronic inflammation.**  

**W2.6**  
**Helicobacter pylori dampens MHC-II expression on macrophages via the up-regulation of miRNAs targeting CIITA**  

**W2.7**  
**H. pylori epigenome micro-evolution associated with DNA methyltransferases’ sequence-specificity changes**  
M. Fukuyo1,2, H. Yano3,4, H. Yonezawa5, N. Takahashi5, K. Yahara6, M. Konno7, T. F. Shibata8, S. Shigenobu8, B. Rahmutulla1, I. Uchiyama8, Y. Hasegawa2, O. Obara2, A. Kaneda1, I. Kobayashi3,5,9, 1Chiba University, Chiba, Japan, 2Kazusa DNA Research Institute, Kisarazu, Japan, 3The University of Tokyo, Tokyo, Japan, 4Tohoku University, Sendai, Japan, 5Kyorin University, Tokyo, Japan, 6National Institute of Infectious Diseases, Tokyo, Japan, 7Sapporo Kosei General Hospital, Sapporo, Japan, 8National Institute for Basic Biology, Okazaki, Japan, 9University Paris-Saclay, Paris, France.

**16.00 – 16.30 hrs**  
**Coffee Break**
PROGRAMME FRIDAY, SEPTEMBER 6

16.30 - 17.30 hrs  State of the Art Lectures  
*Chair: Luiz Coelho, Giovanni Gasbarrini*  
Room Innsbruck

“Test and Treat” strategy with urea breath test: a cost-effective strategy for the management of H. pylori infection in Spain  
Ariel Beresniak, Geneva, Switzerland

The Gut-Brain Axis  
Annemieke Smet, Antwerp, Belgium

17.30 - 19.15 hrs  Parallel Workshops from Submitted Abstracts 3  
Workshop W3. | Treatment of Helicobacter Infection I  
*Room Innsbruck*  
*Chair: Francesco di Mario, Jong Jae Park*

Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)

W3.1  
*Is Helicobacter pylori cure a life-long strategy? A 25 years survey on 693 patients*  
F. Di Mario1, A. Barchi1, M. Russo1, M. Franceschi2, N. Dal Bò3, R. Cannizzaro4, C. Miraglia1, A. Tursi5, G. Brandimarte6, P. Crafa1, L. Franzoni1, M. Rugge7, 1University of Parma-Department of Medicine and Surgery, Parma, Italy, 2Azienda ULSS 7 Pedemontana, Endoscopy Unit-Ospedale Alto Vicentino, Santorso (VI), Italy, 3Gastroenterology and Gastrointestinal Endoscopy Unit, Treviso Hospital, Treviso, Italy, 4Oncological Gastroenterology, CRO Aviano National Cancer Institute, Aviano, Italy, 5Gastroenterology Service, ASL BAT, Andria, Italy, 6Division of Internal Medicine and Gastroenterology, „Cristo Re” Hospital, Rome, Italy, 7Department of Pathology, University of Padova, Padova, Italy.

W3.2  
*High efficacy of 14-day high-dose PPI bismuth-containing quadruple therapy with probiotics supplement for Helicobacter pylori eradication in high clarithromycin resistance areas:A double blinded-randomized placebo-controlled study.*  
P. Poonyam1,2, R. Vilaichone2,3,4, P. Chotivitayatarakorn2,3,4, V. Mahachai3, 1Gastroenterology unit, Faculty of medicine, Srinakharinwirot University, Nakorn Nayok, Thailand, 2Gastroenterology Unit, Thammasat University Hospital, Pathumthani, Thailand, 3National Digestive Diseases Research Center of Thailand, Pathumthani, Thailand, 4Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University, Pathumthani, Thailand.

W3.3  
*The comparison of effectiveness of standard triple therapy and high-dose amoxicillin/bismuth therapy in eradication of H. pylori*  
O. Sjornina1,2, A. Lielaus1, A. Rūdule2, E. Martinsone2, D. Pūpola2,3, R. Vangravs2, A. Kiršners2, S. Paršutins2, H. Gorskis2, I. Poļaka2, A. Jeniceka1, E. Cine1, G. Šķenders2, D. Razuka-Ebela1, M. Leja1,2,4, 1Faculty of medicine, University of Latvia, Riga, Latvia, 2Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia, 3Latvian Biomedical Research and Study centre, Riga, Latvia, 4Digestive Diseases Centre GASTRO, Riga, Latvia.

W3.4  
*A multi-center real-life study on comparison between bismuth quadruple (BQ) (10 days) and clarithromycin (CLA) containing non-bismuth quadruple (CT) therapy (10 and 14 days) in the eradication of H. pylori infection in patients naïve to treatment in a region with high CLA and dual resistance*  
A. G. Gravina1, R. M. Zagari2, G. Nardone3, A. Federico1, M. Dallio1, M. Martorano4, C. Mucherino5, A. Romiti2, L. Vallone1, L. Granata1, L. Colacino1, A. Facchiano1, D. Piccia1, D. Sgambato1, A. Miranda1, L. Romano6, C. Loguercio1, M. Romano1 1Division of Hepatogastroenterology, Department of Precision Medicine, University of Campania „Luigi Vanvitelli”, Naples, Italy, 2Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, 3Division of Gastroenterology, „Federico II” University, Naples, Italy, 4Gastroenterology and Endoscopy Unit, Immunolata Hospital, Sapri, Italy, 5Gastroenterology and Endoscopy Unit, S. Anna-S. Sebastiano Hospital, Caserta, Italy, 6Surgical Digestive Endoscopy, Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
PROGRAMME FRIDAY, SEPTEMBER 6

W3.5

Antibiotic-free Lipid Nanoparticles for Gastric Infection Management

C. L. Seabra1,2,3, P. Parreira1,2, P. Henriques1,2, C. Monteiro1,2, J. Gomes1,4, I. Amorim1,4,5, F. Gartner1,4,5, C. Machado1,2, C. Nunes6, S. Reis6, E. Touati7, C. A. Reis1,4,8, I. C. Gonçalves1,2, M. L. Martins1,2,5, 11S- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, 2INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal, 3CBQF- Centro de Biotecnologia e Química Fina, Universidade Católica Portuguesa (atual affiliation), Porto, Portugal, 4IPATIMUP – Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal, 5ICBAS- Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal, 6REQUIEMTE, Laboratório de Química Aplicada, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal, 7Institut Pasteur, 25-26 Rue du Dr. Roux, 75015, Paris, France, 8Faculdade de Medicina, Universidade do Porto, Porto, Portugal.

W3.6

Fate of meta-analyses: the case of Helicobacter pylori

G. M. Buzás; Ferencváros Health Service Non-Profit Ltd, Budapest, Hungary.

W3.7

Pan-European Registry on H. pylori management (Hp-EuReg): Analysis of 4,388 second-line treatments

O. P. Nyssen1, A. G. McNicholl1, D. Vaira2, A. Perez-Aisa3, B. Tepes4, D. S. Bordin5, F. Lerang6, T. Kokkas7, M. Leja8, A. Axon9, L. Kupcinskiak10, L. Jonaitis1,10, M. Chachadi11, O. Shvets12, L. Veijola13, G. Buzás14, H. Simsek15, L. Boyanoval6, V. Lamy17, Y. Niv18, M. Venerito19, P. Bytzer20, L. G. Capelle21, A. Goldis22, K. Przytulska23, C. Beglinger24, M. Katicic25, T. Miloslavjevic26, G. Fiorini2, M. G. Donday1, F. Megraud27, C. O’Morain28, J. P. Gisbert1, J. H. La Princesa, IIS-IP and CIBERehd, Madrid, Spain, 2S. Orsola Malpighi Hospital, Bologna, Italy, 3Agencia Sanitaria Costa del Sol, Marbella, Spain, 4AM DC Rogaska, Rogaska Slatina, Slovenia, 5Moscow Clinical Scientific Center, Moscow, Russian Federation, 6Central Hospital Ostfold, Fredrikstad, Norway, 7Henry Dunant Hospital, Athens, Greece, 8Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia, 9University of Leeds, Leeds, United Kingdom, 10Lithuanian University of Health Sciences, Kaunas, Lithuania, 11Institute of Investigação e Inovação em Saúde, Universidade do Porto, and Ipatimup - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, 12Internal Diseases Department No.1, National Medical University named after O.O. Bogomolets, Kyiv, Ukraine, 13Internal Medicine, Herttoniemi Hospital, Helsinki, Finland, 14Ferencváros Polyclinic, Budapest, Hungary, 15Hacettepe University Faculty of Medicine, Ankara, Turkey, 16Medical University of Sofia, Sofia, Bulgaria, 17CHU Charleroi, Charleroi, Belgium, 18Rabin Medical Center, Tel Aviv University, Petach Tikva, Israel, 19Otto-von-Guericke University Hospital, Magdeburg, Germany, 20Zealand University Hospital, Copenhagen University, Copenhagen, Denmark, 21Erasmus MC University, Rotterdam, Netherlands, 22Timisoara Hospital, Timisoara, Romania, 23Medical Centre for Postgraduate Education, Warsaw, Poland, 24Medical Centre for Postgraduate Education, Warszawa, Poland, 25University Hospital Merkur Polyclinic Nola, Zagreb, Croatia, 26Clinical Center of Serbia Clinic for Gastroenterology and hepatology, University of Belgrade, Belgrade, Serbia, 27Hôpital Pellegrin, Bordeaux, France, 28Trinity College Dublin, Dublin, Ireland.

W3.8

Current treatment of Helicobacter pylori infected children and adolescents in Europe: Interim Results of the new EuroPedHp Registry

T. Le Thi1, K. Werksetter1, J. Cabral2, K. Kotilea3, P. Bontems3, M. Cillereulo Pascual4, J. Barrio5, M. Homan6, M. Kori7, P. Urruzuno8, N. Kalacho9, Z. Misak10, R. Lima11, M. Tavares12, E. Miele12, A. Chiaro13, V. Urbonas14, K. Matusiewics15, A. Krail16, M. Korkut Ugras17, A. Papadopoulou18, F. Rea19, J. Sykora20, J. de Laffolie21, M. Klenak22, M. Rogalidou23, E. Roma24, A. Lopes25, T. Casswall26, A. Cseh27, H. Banoub28, S. Koletzko1, and the Helicobacter pylori Working Group of ESPGHAN, 1Dr. von Hauner Children’s Hospital, Medical center of the University of Munich, Munich, Germany, 2Hospital of Dona Estefania, CHLC, Lisbon, Portugal, 3Queen Fabiola Children’s Hospital University, Brussels, Belgium, 4Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 5Hospital Universitario de Fuenlabrada Madrid, Madrid, Spain, 6University Children’s Hospital Ljubljana, Ljubljana, Slovenia, 7Kaplan Medical Center, Petach Tikva, Israel, 19Otto-von-Guericke University Hospital, Magdeburg, Germany, 20Zealand University Hospital, Copenhagen University, Copenhagen, Denmark, 21Erasmus MC University, Rotterdam, Netherlands, 22Timisoara Hospital, Timisoara, Romania, 23Medical Centre for Postgraduate Education, Warsaw, Poland, 24Medical Centre for Postgraduate Education, Warszawa, Poland, 25University Hospital Merkur Polyclinic Nola, Zagreb, Croatia, 26Clinical Center of Serbia Clinic for Gastroenterology and hepatology, University of Belgrade, Belgrade, Serbia, 27Hôpital Pellegrin, Bordeaux, France, 28Trinity College Dublin, Dublin, Ireland.
**Programme Friday, September 6**

**17.30 - 19.15 hrs**  
**Parallel Workshops from Submitted Abstracts 4**  
**Workshop W4. | Gastric Carcinogenesis**  
*Room Brussels*

*Chair: José Machado, Yaron Niv*

*Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)*

**W4.1**  
**Understanding the tumour-promoting functions of autophagy in gastric carcinogenesis**  
N. Castano Rodriguez1, A. B. Goswami1, I. Simovic1, H. M. Mitchell1, N. O. Kaakoush1, K. M. Fock2, K. L. Goh3, G. L. Porras-Hurtado4, J. L. Cardona-Deazza4, J. J. Montoya-Martinez4,  
The University of New South Wales, Sydney, Australia, 2Changi General Hospital, Singapore,  
Singapore, 3University of Malaya, Kuala Lumpur, Malaysia, 4Clínica Comfamiliar Risaralda,  
Pereira, Colombia.

**W4.2**  
**Molecular characterization of the gastric commensal bacteria progressing gastric carcinogenesis in *Helicobacter pylori*-infected gastric mucosa**  
H. Tsugawa1, J. Matsuoka1, H. Mori2, M. Suematsu1, H. Suzuki3,  
1Keio University, Tokyo, Japan, 2National Hospital Organization Tokyo Medical Center, Tokyo, Japan, 3Tokai University, Kanagawa, Japan.

**W4.3**  
**“Helicobacter pylori-activated gastric fibroblasts induce permanent reprogramming of gastric epithelial cells towards invasive phenotype in vitro”**  
G. Krzyziek-Maczka1, A. Targosz1, M. Strzalka1, U. Szczyrk1, A. Ptak-Belowska1, J. Czyz2,  
T. Brzozowski1, 1Department of Physiology, Jagiellonian University Medical College, Cracow,  
Poland, 22Department of Cell Biology, the Faculty of Biochemistry, Biophysics and Biotechnology,  
Jagiellonian University, Cracow, Poland.

**W4.4**  
**Identification of novel serological biomarkers for gastric cancer in the MCC-Spain case-control study based on *Helicobacter pylori* whole-proteome microarrays**  
R. Jeske1, D. Reininger1, J. A. Butt1,2, C. Harmel1, B. Turgo1, N. Fernández de Larrea-Baz3,4,  
V. Martin4,5, V. Moreno4,6, M. Kogevinas4,7, M. Pollán3,4, T. Waterboer1,  
N. Aragonés4,8, M. Pollán3,4, T. Waterboer1, 1German Cancer Research Center (DKFZ), Heidelberg, Germany, 2Duke Cancer Institute and Duke University, Durham, NC, United States, 3National Center of Epidemiology, Carlos III Health Institute (ISCIII), Madrid, Spain, 4CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain, 5University of León, León, Spain, 6Catalan Institute of Oncology (ICO), Hospital de Llobregat, Barcelona, Spain, 7Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, 8Department of Health, Madrid, Spain.

**W4.5**  
**Risk of progression of intestinal metaplasia in a low gastric cancer incidence country.**  
A. Bowden, J. Weininger, E. Farrell, S. Crowther, D. McNamara, C. O’Morain, A. O’Connor,  
Tallaght University Hospital/Trinity College Dublin, Dublin, Ireland.

**W4.6**  
**Prevention of *Helicobacter pylori*-associated gastric carcinogenesis with dietary walnut**  
K. Hahm1, Y. Shin2,  
1CHA University, Seongnam, Republic of Korea, 2Inha University, Incheon, Republic of Korea.

**W4.7**  
**Role of Leukaemia Inhibitory Factor (LIF) on the tumorigenic properties of Cancer Stem Cells in gastric adenocarcinoma**  
L. Seeenevassent1, J. Giraud1, S. Molina-Castro2, C. Tiffon1, C. Staedel1, O. Martin1, F. Mégraud1,4, P. Lehours1,4, H. Boeuf5, P. Dubus1,4, C. Varon1,  
1INSERM U1053 BarITOn, University of Bordeaux, Bordeaux, France, 2INISA-School of Medicine, University of Costa Rica,  
San José, Costa Rica, 3INSERM U1212 Régulations Naturelles et Artificielles des ARNs, University of Bordeaux, Bordeaux, France, 4CHU de Bordeaux, Bordeaux, France, 5INSERM U1026, Bordeaux, France.

**W4.8**  
**IL-27 is abrogated in the gastric mucosa and serum of patients with gastric cancer in opposite to duodenal ulcer**  
D. M. M. Queiroz1, F. F. Melo2, M. M. D. A. Cabral1, B. B. Brito2, F. A. F. Silva2, G. A. Rocha1,  
1Universidade Federal de Minas Gerais/Faculdade de Medicina, Belo Horizonte, Brazil, 2Universidade Federal da Bahia, Vitória da Conquista, Brazil.

**20.00 hrs**  
**Networking Dinner at the Restaurant Stiftskeller**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 08.00 - 09.40 hrs| **Symposium: Modulation of microbiota**<br>
Chair: Georgina Hold, Patrizia Kump<br>Room Innsbruck |            |
| 08.00 - 08.20    | Diet: a major confounder of the gut microbiota<br>Alexander Moschen, Innsbruck, Austria |            |
| 08.20 - 08.40    | Probiotics – how and when do they work?<br>Mirjana Rajilic-Stojanovic, Belgrade, Serbia |            |
| 08.40 - 09.00    | Pre-/pro-/antibiotics: how to best manipulate the microbiota?<br>Laure Bindels, Louvain, Belgium |            |
| 09.00 – 09.20    | FMT: indications and potential<br>Gianluca Ianiro, Rome, Italy |            |
| 09.20 - 09.40    | New Stool Biobanking Initiative<br>Josbert Keller, Den Haag, The Netherlands |            |
| 09.40 – 10.30 hrs| **Coffee Break**                                                        |            |
| 10.30 - 11.50 hrs| **Symposium: Helicobacter and other Microbiota in Extragastric Diseases**<br>Room Innsbruck |            |
| 10.30 - 10.50    | Autoimmune & Allergic Disorders<br>Maria Pina Doré, Sassari, Italy |            |
| 10.50 - 11.10    | Metabolic Syndrome & Asthma<br>Nayoung Kim, Seoul, Korea |            |
| 11.10 - 11.30    | Atherothrombosis<br>Christoph Reinhardt, Mainz, Germany |            |
| 11.30 - 11.50    | Neurodegenerative diseases<br>Claire Roubaud, Bordeaux, France |            |
| 12.00 - 13.00 hrs| **Symposium: Modulation of microbiota**<br>Chair: David Graham<br>Please see page 22 for details |            |
| 13.00 - 14.00 hrs| Lunch Break & Poster Viewing |            |
| 14.00 - 15.30 hrs| **Parallel Workshops from Submitted Abstracts 5**<br>Room Innsbruck |            |
|                  | Workshop W5. | Treatment of Helicobacter Infection II<br>Chair: Javier Gisbert, Athanasios Makristhatis |            |
| W5.1             | Helicobacter pylori Acid Acclimation: The Evil Duo of a pH-Gated Urea Channel and a Cytoplasmic Urease<br>H. L. Luecke, E. Cunha, University of Oslo, Oslo, Norway. |            |
Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of *Helicobacter pylori*. T. Furuta, M. Yamada, T. Kagami, T. Suzuki, T. Higuchi, T. Uotani, S. Tani, M. Iwaizumi, Y. Hamaya, S. Osawa, K. Sugimoto, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Ten-day concomitant, 10-day sequential, and 7-day triple therapy in first-line treatment of *Helicobacter pylori* infection: a randomized nationwide trial in Korea. B. Kim1, H. Lee2, J. Kim1, J. Kim2, Korean College of Helicobacter and Upper Gastrointestinal Research, 1Chung-Ang University Hospital, Seoul, Republic of Korea, 2SungKyunKwan University College of Medicine, Seoul, Republic of Korea.

Effect of Previous Nitroimidazole Treatment on *Helicobacter pylori* Eradication Success. D. Boltin1, Z. Levi1, R. Gindgold-Belfer1, T. Shochat1, I. Dotan1, S. Birkenfeld2, Y. Niv3, 1Rabin Medical Center, Petah Tikva, Israel, 2Clalit Health Services, Tel Aviv, Israel, 3Ministry of Health, Jerusalem, Israel.

Growing *H. pylori* resistance to standard antibiotic therapies identified from a phase 3 clinical trial of treatment naive patients in the United States. D. Y. Graham1, K. G. Hulten1, L. B. Lamberth1, R. M. Panas2, I. N. Kaufs3, 1Baylor College of Medicine, Houston, TX, United States, 2RedHill Biopharma, Inc., Raleigh, NC, United States, 3RedHill Biopharma Ltd., Tel Aviv, Israel.

European survey of *Helicobacter pylori* primary resistance to antibiotics - Evolution over the last 20 years. F. Mégraud1, D. Huang2, M. Hoebeké2, C. Aïx1, L. Bénéjat1, P. Lehours1, Y. Glupczynski2, The H. pylori AST Working Group, 1National Reference Centre for Helicobacters, Bacteriology Laboratory, Pellegrin Hospital, Bordeaux, France, 2National Reference Centre for Helicobacters, Bacteriology Laboratory, CHU UCL Namur (Site Godinne), Yvoir, Belgium.

The activity of liposomal linolenic acid against *Helicobacter pylori* in vitro and its impact on human fecal microbiota. Y. Wang1,2; S. Wu1; Y. An1,2; Y. Wang1; Y. He1; Y. Fu3; Y. Xie1, 1Department of Gastroenterology, Nanchang, China; 2School of Pharmacy, Nanchang University, Nanchang, China; 3School of Pharmacy, Nanchang, University, Nanchang, Nanchang, China.

**Parallel Workshops from Submitted Abstracts 6**

**Workshop W6. | Microbiota in Health and Disease**

Room Brussels

Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)


**W6.2** Combining nucleic acid mimics and spectral imaging with fluorescence in situ hybridization for the analysis of the gastric micro-biogeography. A. S. Azevedo1,2,3, H. Teixeira1, R. Ferreira2,3, C. Figueiredo2,3, J. Wengel4, C. Almeida1,5,6, N. Azevedo1, 1LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465, Porto, Portugal, 23S Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, 3IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, 4Nucleic Acid Center, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark, 5National Institute for Agrarian and Veterinary Research (INIAV), Rua dos Lagidos, Lugar da Madalena, 4485-655 Vairão, Vila do Conde, Portugal, 6Centre of Biological Engineering, Universidade do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.

**W6.3** Patients with small intestinal bacterial overgrowth (SIBO) have distinct microbiome characteristics including post *Helicobacter pylori* eradication treatment. T. T. Perets1,2, O. Ashorov1, D. Hamouda1, S. Ben Simon3, D. Boltin4,2, O. Koren3, R. Dickman4,2, 1Rabin Medical Center - Gastroenterology Laboratory, Petah Tikva, Israel, 2Tel Aviv University - Sackler Faculty of Medicine, Tel Aviv, Israel, 3Bar Ilan University - Azrieli Faculty of Medicine, Zefat, Israel, 4Rabin Medical Center - Division of Gastroenterology, Petah Tikva, Israel.
W6.4  The difference of gut microbiome in the stage of colorectal cancer and change of gut microbiome after surgery or chemotherapy
J. Cho1, D. Lee1,2, Y. Lee2, M. Seol2, Y. Kim3, W. Lee4, Y. Kim4, Y. Park1, C. Shin1, H. Yoon1, N. Kim1, S. Seol5, 1Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 2R&D center, BioBankHealing Inc., Seongnam, Republic of Korea, 3Graduate School of Medical Science & Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, 4MD Healthcare Inc., Seoul, Republic of Korea, 5Inje University Busan Paik Hospital, Busan, Republic of Korea.

W6.5  Microbiota changes induced by Microencapsulated Sodium Butyrate
S. Facchin1, N. Vitulo2, M. Calgaro2, A. Buda3, R. Chiara4, B. Perini1, G. Lorenzon1, C. Marinelli1, E. Savarino1, 1University of Padua, DISCOG,Padua, Italy, Padua, Italy, 2University of Verona, Department of Biotechnology, Verona, Italy, 3UOC Gastroenterology, Feltre, Belluno, Italy, 4University of Padua, Department of Biology, Padua, Italy.

W6.6  Saccharomyces boulardiiCNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome
P. Cardenas1, M. Baldeon2, H. Cohen3, M. Fornasini4, D. Garces5, B. Prado5, N. Flores4, I. Salvador4, O. Cargua4, 1Instituto de Microbiologia - Universidad San Francisco de Quito, Quito, Ecuador, 2CENBIO - Universidad UTE, Quito, Ecuador, 3Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay, 4CENBIO, Quito, Ecuador, 5Instituto de Microbiologia, Quito, Ecuador.

W6.7  Efficacy and safety of new Lactobacilli mixture in patients with unconstipated irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial
O. Joo Hyun1, Y. Jang1, D. Kang2,3, D. Chang1, Y. Min1, 1Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea, 2Department of Clinical Research Design and Evaluation, Samsung Medical Center, Seoul, Republic of Korea, 3Center of Clinical Epidemiology, Samsung Medical Center, Seoul, Republic of Korea.

15.30 – 16.00 hrs  Coffee Break

16.00 - 17.30 hrs  Symposium: Treatment of H. pylori infection
Chair: Jyhming Liou, Peter Malfertheiner
Room Innsbruck

16.00 - 16.20  Efficacy of empirical vs. guided treatment
Liou JM, Taipei, Taiwan

16.20 - 16.50  Monitoring antibiotic resistance, when and how?
A French perspective
Francis Mégraud, Bordeaux, France

A Korean perspective
Hwoon-Yong Jung, Seoul, Korea

16.50 - 17.10  Where are we with a vaccine?
David Graham, Houston, TX, USA

17.10 - 17.30  Beyond antibiotics
Niyaz Ahmed, Dhaka, Bangladesh
17.30 - 18.00 hrs  Debate: Is *Helicobacter pylori* relevant in oesophageal diseases?  
*Chair: Günter Krejs, Colm O’Morain*  
Room Innsbruck  

Yes  
Francesco Di Mario, Parma, Italy  

No  
Peter Malfertheiner, Munich, Germany

18.00 - 18.30 hrs  Closing Session  
*Chair: Georgina Hold, Francis Mégraud, Herbert Tilg*  
Room Innsbruck

Awarding of the Marshall and Warren Medal to Guillermo Perez-Perez  
EHMSG Presentation and Poster Awards  
Presentation of the next meeting in Glasgow, United Kingdom  
Closing remarks
SPONSORED SATELLITE SYMPOSIUM

Saturday, September 7, 2019

12.00 - 13.00 hrs  Industry Sponsored Satellite Symposium

**H. pylori treatment and Microbiome research in China**

*Chair: David Graham, Houston, TX, USA*

12.00 - 12.20 hrs  Bismuth plus triple therapy adjusted according to medication history in the first-line eradication of *Helicobacter pylori* infection: a randomized trial

Prof. Liya Zhou

12.20 - 12.40 hrs  The management of drug resistant *Helicobacter pylori* in China

Prof. Rong Lin

12.40 - 13.00 hrs  *Helicobacter Pylori*, Microbiome and Gastric Cancer

Prof. Jun Yu

---

**RICHEN EUROPE S.R.L.**

**COMPANY OF RICHEN GROUP**
SCIENTIFIC INFORMATION

Oral Presentations

Commercial Disclosure information
Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.
If you have nothing to disclose, please state “I have no commercial disclosure” instead of the table.

Speaking Time
The chairpersons of your session will be strict in allowing no more than the time allotted to your presentation. Remember to allow some time for the changeover of speakers and chairperson’s introduction, and for questions and discussion.
Make yourself known to the chairpersons and/or the technician in your session room before the beginning of the session.

Projection and Technical Settings
All rooms are equipped with Windows 10 and data projector for Power Point presentation (PPT 2016) only.

Presentation Format 16:9

Handing in Your Presentation:
It must then be handed over to the technician of the according lecture room in a break at least 2 hours before your talk either via USB-Memory Stick or USB-External Drives (30 minutes for talks in the first morning sessions).

General hints and tips
Like all of us, you will have sat through many conference talks, some good and some bad. We have all been to talks which failed to communicate their message because the speaker spoke impossibly fast, perhaps in a very indistinct way, or flashed through large numbers of slides so crammed with detail that nobody could follow them.
So please:
• Make yourself known to the chairpersons and/or the room assistant in your session room before the beginning of the session.
• Remember that the vast majority of the audience are not native English speakers - speak clearly (whether or not English is your native tongue) and not too fast
• Plan an average of no more than 1 slide per minute, in most cases
• Keep your Powerpoints simple. In text slides, use no more than ten lines per slide, with ample space between the lines, and no more than seven words per line in suitably large lettering
• Leave sufficient space between the text and the edge of the slide/screen.
Some data projectors may not display the very border of the slide/presentation.
Poster Presentations

IMPORTANT NOTE: Posters are on display for two days. Posters need to be taken off by the author at the end of the conference. Posters not removed until then will be removed by the staff. Posters will be discarded, and neither kept, stored nor sent to the authors after the meeting. Please note that the organisers cannot assume any liability for loss, theft or damage of posters displayed in the poster area.

Mounting of posters is possible on Friday, September 6, 2019 from 8.00 - 10.00 hrs. Removal on Saturday, September 7, 2019, from 15.00-17.30 hrs.

You will find your poster board number in the author index of the abstract book, which you have received at the registration desk.

The presence at the poster of one of the authors is mandatory during the following times:

**Friday, September 6, 2019**

Poster Round 1
- Treatment of Helicobacter infection - P1.1 (P1.01 - P1.52)
- Drug resistance and Clinical Issues P1.2 (P1.53 - P1.70)

Poster Round 2
- Helicobacter and extragastroduodenal disease P2.1 (P2.01 - P2.11)
- Gastric microbiota P2.2 (P2.12 - P2.19)
Chairs: Ceu Figueiredo, Juozas Kupcinskas

Poster Round 3:
- Gut microbiota in health and disease P3.1 (P3.01 - P3.38)
Chairs: Timon-Erik Adolph, Gianluca Ianiro, Francesco Franceschi, Patrizia Kump, Patricia Lepage, Alexander Moschen

**Saturday, September 7, 2019**

Poster Round 4:
- 01. Diagnosis of Helicobacter infection P4.1 (P4.01 - P4.14)
- 06. Epidemiology P 4.2 (P4.15 - P4.31)
- 10. Paediatrics P4.3 (P4.32-P4.42)
Chairs: Leif P. Andersen, Luiz Coelho, Marcis Leja, Maria Effenberger, Varocha Mahachai, Francis Mégraud

Poster Round 5:
- 04. Gastric cancer and cancerogenesis P5.1 (P5.01 - P5.37)
Chairs: José C. Machado, Ari P. Ristimäki, Massimo Rugge, Chung-Ying Wu

Poster Round 6:
- 05. Virulence factors and pathogenesis of Helicobacter infection P6.1 (P6.01 - P6.19)
- 07. Inflammation, immunity, vaccines and host interaction P6.2 (P6.20 - P6.32)
- 08. Microbiology and genomics of Helicobacter P6.3 (P6.33 - P6.36)
Chairs: Niyaz Ahmed, Mario Milco D’Elios, James G. Fox, Yoshio Yamaoka

**Format**
The usable surface on the poster board is 90 cm width x 150 cm height (portrait format). Adhesive material will be made available.
Acknowledgements

The organisers gratefully acknowledge the support of the following institutions and companies for the EHMSG 2019 Workshop:

- RICHEP EUROPE S.R.L.
- MAYOLY SPINDLER
- ALFASIGMA
- BIOCODEX
- INFAI
- meridian BIOSCIENCE™
- MOBIDING
- MP
- WILEY

The organisers gratefully acknowledge the support of the following company for the EHMSG 2019 Postgraduate Course:

- FERRING PHARMACEUTICALS
GENERAL INFORMATION

In alphabetical order.

Badges
Participants should collect name badges from the conference registration desk. As only registered participants will be permitted to attend the Scientific Sessions, the Exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.

Cancellations and Refunds
Notice of cancellation had to be made in writing by email or fax to the Congress Office.
The policy for refunding registration fees is as follows:
Written cancellation received:
- Before July 31, 2019: 50% refund
- After July 31, 2019: no refund
The date of the email or fax ID is the basis for considering refunds. Refunds will be made after the congress.

Certificate of Attendance
Confirmations of attendance will be issued at the registration desk.

Cash Dispensers
ATMs are widely available in Innsbruck. Local currency (Euro) can also be obtained from banks and exchange bureaus.

CME Credits
The “XXXIInd International Workshop on Helicobacter and Microbiota in Inflammation and Cancer” was granted a total of 14 European CME credits (ECMEC) the Postgraduate Course on “Microbiota: from metabolism to immunity and fecal microbial transplantation-pearls for the clinician” was granted a total of 6 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Coffee Breaks and Lunch
During the session breaks refreshments (coffee, tea, and water) will be served free of charge to participants wearing name badges. Lunch tickets for Friday and Saturday had to be pre-ordered and cannot be purchased on site. Lunch tickets are not refundable.

Congress Venue
XXXIIInd Workshop of the EHMSG:
Congress Innsbruck
Rennweg 3
6020 Innsbruck, Austria

Currency
The official currency of Austria is the Euro (EUR).
1 EUR = 1,12 USD = 0,93 GBP = 129 JPY = 1,08 CHF = 7,46 SEK = 1,65 AUD = 1,48 CAD
as per date of printing

Electricity Supply
In Austria the standard voltage is 230 V and the frequency is 50 Hz. You can use your electric appliances in Austria, if the standard voltage in your country is in between 220 - 240 V (as is in the UK, Europe, Australia and most of Asia and Africa). Socket Type F („Schuko“)

GSM cell phone roaming
GSM cell/mobile phone roaming is available without any problems for all major international providers. It is advisable to inquire at your provider which roaming company in Austria offers the cheapest tariffs for non-EU contracts.
Internet
You will find Internet cafés throughout the city. WiFi is available at the conference venue please use the ehmsg2019 for username and password.

Language
The official language of the workshop is English (no simultaneous translation).

Liability
In registering for the EHMSG 2019 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements in respect of health and travel. Furthermore, the organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the Exhibition at the Conference venue
EHMSG Postgraduate Course & EHMSG Far East Symposium
Thursday, September 5, 2019: 07.30 – 19.00 hrs
EHMSG Workshop
Friday, September 6, 2019: 07.30 – 19.15 hrs
Saturday, September 7, 2019: 07.30 – 18.30 hrs

Poster Removal
The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. Posters that were not removed after the end of the respective day of display, will be removed and will not be kept nor mailed to the author after the meeting. See detailed in formation in the “scientific information” section of the program.

Presentations
All presenters should hand in their electronic presentation to the technician of the according lecture room in a break at least 2 hours before your talk either via USB-Memory Stick or USB-External Drives (30 minutes for talks in the first morning sessions).

Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide.
A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.
If you have nothing to disclose, please state “I have no commercial disclosure” instead of the table.

Safety - Crime
Visitor safety is generally adequate, like in any other major European city. You can walk everywhere using common sense. Pick pocketing in heavily visited tourist zones or in public transport lines might be a concern. Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:
- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a Xerox copy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference venue, it will make you easily identifiable as a tourist.

Smoking Policy
The EHMSG 2019 Workshop is a “No-smoking-Conference”.

Staff
If you should have any questions, the congress staff will be pleased to help you.
## Registration Details

### Registration Fees

<table>
<thead>
<tr>
<th>Payment received</th>
<th>Before July 12, 2019</th>
<th>After July 12, 2019 &amp; on site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Participants</td>
<td>EUR 320.–</td>
<td>EUR 420.–</td>
</tr>
<tr>
<td>Young Scientists (&lt;35 years)</td>
<td>EUR 170.–</td>
<td>EUR 220.–</td>
</tr>
<tr>
<td>Students (&lt;30 years)</td>
<td>EUR 110.–</td>
<td>EUR 110.–</td>
</tr>
<tr>
<td>Company Representatives</td>
<td>EUR 450.–</td>
<td>EUR 550.–</td>
</tr>
<tr>
<td>Member of the Paediatric Task Force</td>
<td>EUR 220.–</td>
<td>EUR 250.–</td>
</tr>
<tr>
<td>Day Ticket - Regular / Young Scientist / Student</td>
<td>-</td>
<td>EUR 220.– / 145.– / 80.–</td>
</tr>
<tr>
<td>Postgraduate Course ONLY</td>
<td>EUR 150.–</td>
<td>EUR 170.–</td>
</tr>
<tr>
<td>Combined Fee EHMSG &amp; Postgraduate Course - Regular Participants</td>
<td>EUR 420.–</td>
<td>EUR 520.–</td>
</tr>
<tr>
<td>Combined Fee EHMSG &amp; Postgraduate Course - Young Scientists</td>
<td>EUR 270.–</td>
<td>EUR 320.–</td>
</tr>
<tr>
<td>Combined Fee EHMSG &amp; Postgraduate Course - Students</td>
<td>EUR 210.–</td>
<td>EUR 210.–</td>
</tr>
<tr>
<td>Combined Fee EHMSG &amp; Postgraduate Course - Company Representatives</td>
<td>EUR 550.–</td>
<td>EUR 650.–</td>
</tr>
<tr>
<td>Combined Fee EHMSG &amp; Postgraduate Course - Paediatric Task Force</td>
<td>EUR 320.–</td>
<td>EUR 350.–</td>
</tr>
<tr>
<td>Networking Event, September 5, 2019</td>
<td>---*</td>
<td>---*</td>
</tr>
<tr>
<td>Networking Dinner, September 6, 2019</td>
<td>EUR 65.–</td>
<td>EUR 65.–**</td>
</tr>
<tr>
<td>Lunch tickets (per day)</td>
<td>EUR 15.–</td>
<td>---***</td>
</tr>
</tbody>
</table>

* no fee but registration is mandatory, registering for tickets on site is subject to availability
** Purchasing tickets on site is subject to availability
*** Lunch tickets had to be pre-ordered and cannot be purchased on site

### Payment of Registration fees

Payment of Registration fees may be made either cash in Euro or by Credit Card (Diners Club, Mastercard and Visa).

### Please note

The reduced registration fee was only applicable, if it has been credited to the congress account before the deadline. Registering before July 12, 2019 without performing an actual payment was not sufficient to benefit from the reduction.

### What is covered by the registration fee?

- Admission to all scientific sessions and the exhibition
- Admission to the networking mixer (subject to availability)
- Programme book
- Abstract Book
- Refreshments during coffee breaks
Networking Events

Thursday, September 5, 2019, 19.00 hrs

Networking Event at the Conference Venue
Free for registered participants, however registration for this event is mandatory.

Friday, September 6, 2019, 20.00 hrs

EHMSG Networking Evening at the Restaurant Stiftskeller
A ticket is required and will be checked at the entrance - EUR 65,- per ticket
When something happens in the microbiota realm, you can be sure to find it online.

Biocodex, a French laboratory with an international scope, has launched a reference website for the human microbiota. On BMI-PRO.com, you’ll find essential information to help you better understand microbiota and find out how they interact with diseases. You’ll also get the latest news and learn about every exciting new discovery.

Master microbiota? With BMI-PRO.com, you can.
When something happens in the microbiota realm, you can be sure to find it online. Biocodex, a French laboratory with an international scope, has launched a reference website for the human microbiota. On BMI-PRO.com, you'll find essential information to help you better understand microbiota and find out how they interact with diseases. You'll also get the latest news and learn about every exciting new discovery. Master microbiota? With BMI-PRO.com, you can.
Helicobacter Test INFAI®

One of the most used $^{13}$C-urea breath tests for the diagnosis of Hp-infections worldwide

- New line of INFAI packaging according the EU’s Falsified Medicines Directive
- More than 6.4 million Helicobacter Test INFAI performed worldwide
- Registered in more than 40 countries worldwide
- First approved Hp test for children from the ages of 3 to 11
- Modified Hp test for patients taking PPIs (REFEX)
- Cost-effective CliniPac Basic for hospital and GPs use

INFAI GmbH
Gottfried-Hagen Straße 60-62
D-51105 Cologne

Phone: +49 221 880 44-3
Fax: +49 221 880 44-55
Email: mail@infai.de, info@infai.co.uk
Web: www.infai.de, www.infai.co.uk